ArticleFrontiers in microbiology2026
Advanced applications of cationic photosensitizer DHPC in photodynamic eradication of drug-resistant bacteria.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) is increasingly viewed as a reliable and effective treatment for infections caused by antibiotic-resistant bacteria. However, the limited uptake of photosensitizers (PS) by bacteria remains a major challenge. Cationization enables PS to accumulate around bacterial cells, thereby promoting their intracellular delivery. In particular, cationic small-molecule PS are characterized by carrier-free bacterial enrichment, efficient biofilm penetration, high stability, straightforward synthesis, and moderate charges that minimize toxicity, making them a sustained focus in antimicrobial PS development. Herein, we investigate the potential of a cationic small-molecule PS, DHPC [(E)-8-(diethylamino)-2-(4-(diethylamino)-2-hydroxystyryl)-4-oxo-4H-pyrano[2,3-b]chromen-10-ium], for combating drug-resistant pathogens. Our results demonstrate that DHPC-mediated PDT (DHPC-PDT) effectively eradicates drug-resistant bacteria, including antibiotic-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.